U.S. Stem Cell Stock Price, News & Analysis (OTCMKTS:USRM) Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket Capitalization$70,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest About U.S. Stem Cell Stock (OTCMKTS:USRM)U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.Read More USRM Stock News HeadlinesNovember 29, 2023 | msn.comAdults with rare blood disorder to be offered stem cell transplantsNovember 28, 2023 | nypost.comHope for MS sufferers as doctors ‘cautiously very excited’ about stem cell therapy in brainNovember 30, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 28, 2023 | yahoo.comNewly discovered spine stem cells help explain cancer metastasis in boneNovember 28, 2023 | msn.comStem cell injection may protect against decline in MSNovember 27, 2023 | msn.comMS could be cured by injecting stems cells into brain, Cambridge scientists findNovember 27, 2023 | yahoo.comMultiple sclerosis stem cell treatment breakthrough could stop disease in its tracks, study findsNovember 27, 2023 | msn.com'Exciting' stem cell breakthrough could lead to treatment for MSNovember 30, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 27, 2023 | msn.comStem cell treatment could halt progress of multiple sclerosisNovember 18, 2023 | msn.comFrom the India Today archives (2010) | How stem cells can save your lifeNovember 16, 2023 | msn.comChildren's doctor searching for blood stem cell donor after leukemia diagnosisNovember 8, 2023 | msn.comGeneral Hospital Star John J. York Begins Stem Cell TransplantNovember 3, 2023 | markets.businessinsider.comDynamic Stem Cell Therapy Uncovers Research in Advance Regenerative MedicineOctober 27, 2023 | forbes.comOpening Our Eyes To Stem Cells For Stargardt's Macular DystrophyOctober 20, 2023 | msn.comHas Anyone had Stem Cell treatmentOctober 18, 2023 | mirror.co.ukInjecting stem cells from discarded heart tissue can treat Crohn's, study findsOctober 16, 2023 | msn.comMedical professionals ask Health Ministry to help stop 'illegal' practice of stem cell therapyOctober 6, 2023 | news.yahoo.comGerman stem cell transplant donor comes to Watertown to meet the man he savedOctober 4, 2023 | msn.comScientists 3D-print stem cells that can be implanted as brain tissueSeptember 28, 2023 | msn.comSummerlin Hospital hosts bone marrow drive for stem cell donorsSeptember 16, 2023 | us.cnn.comNIH announces owners of stem cellsSeptember 16, 2023 | us.cnn.comThompson: Stem cell lines 'viable for research'September 12, 2023 | markets.businessinsider.comHow Stem Cell Vet Is Revolutionising Veterinary Care: Introducing 3-Year Payment PlansSeptember 11, 2023 | msn.comFDA clears drug to help harvest stem cells to treat multiple myeloma patientsAugust 30, 2023 | msn.comIn a First, Scientists Fully Wipe a Cell's Memory Before Turning It Into a Stem CellAugust 25, 2023 | forbes.comHow mRNA Could Safely Replace Blood Stem Cell TransplantationSee More Headlines Receive USRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for U.S. Stem Cell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2019Today11/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:USRM Previous SymbolNASDAQ:BHRT CUSIPN/A CIK1388319 Webwww.us-stemcell.com Phone(954) 835-1500Fax954-845-9976Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$80,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / BookN/AMiscellaneous Outstanding Shares661,510,000Free Float550,903,000Market Cap$70,000.00 OptionableNot Optionable Beta-0.75 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Michael Tomas (Age 57)CEO, President, CFO & Director Dr. Colleen RobbSenior Compliance OfficerMr. Phil PosaSenior Vice President of U.S. & International SalesMs. Evelyn FloresCorporate ControllerDr. Sergio PinskiMedical Director & Member of Scientific Advisory BoardKey CompetitorsAffinity Energy and HealthOTCMKTS:ALGXYDeltagenOTCMKTS:DGENDNAPrint GenomicsOTCMKTS:DNAGProtalexOTCMKTS:PRTXRedpoint BioOTCMKTS:RPBCView All Competitors USRM Stock Analysis - Frequently Asked Questions How were U.S. Stem Cell's earnings last quarter? U.S. Stem Cell, Inc. (OTCMKTS:USRM) issued its earnings results on Wednesday, August, 7th. The company reported $0.00 EPS for the quarter. The firm had revenue of $1.30 million for the quarter. What other stocks do shareholders of U.S. Stem Cell own? Based on aggregate information from My MarketBeat watchlists, some companies that other U.S. Stem Cell investors own include Orion Energy Systems (OESX), Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), Axsome Therapeutics (AXSM) and How do I buy shares of U.S. Stem Cell? Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:USRM) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding U.S. Stem Cell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.